Inovio Pharmaceuticals

INOVIO is a biotechnology company focused on rapidly bringing precisely designed DNA medicines to market to treat and protect people from infectious diseases, cancer, and HPV-related conditions. INOVIO is the first and only company clinically proven to deliver DNA medicines directly into cells in the body via proprietary smart devices, thereby producing robust and tolerable immune responses. Specifically, INOVIO’s lead candidate, VGX-3100, is currently in Phase 3 trials for precancerous cervical dysplasia and has demonstrated destruction and clearance of high-risk HPV 16 and 18 in Phase 2b clinical trials. Additionally, programs targeting HPV-related cancers and rare HPV-related diseases such as recurrent respiratory papillomatosis; non-HPV-related cancers including glioblastoma multiforme and prostate cancer; and externally funded infectious disease DNA vaccine development programs related to COVID-19 and MERS, Zika virus, Lassa fever, Ebola virus, and HIV are under development.